Compare BRN & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BRN | BIVI |
|---|---|---|
| Founded | 1956 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.4M | 13.3M |
| IPO Year | 1995 | 2013 |
| Metric | BRN | BIVI |
|---|---|---|
| Price | $1.04 | $1.90 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 62.0K | ★ 167.1K |
| Earning Date | 05-14-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $13,697,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.92 | $0.88 |
| 52 Week High | $1.40 | $9.09 |
| Indicator | BRN | BIVI |
|---|---|---|
| Relative Strength Index (RSI) | 43.08 | 63.11 |
| Support Level | $0.99 | $1.17 |
| Resistance Level | $1.14 | $2.07 |
| Average True Range (ATR) | 0.04 | 0.17 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 25.02 | 64.88 |
Barnwell Industries Inc is an oil and gas company engaged in the acquisition, development, production, and sale of crude oil and natural gas. The Company operates through two segments: the Oil and Natural Gas segment, which focuses on oil and natural gas development, production, acquisitions, and sales in the United States and Canada; and the Land Investment segment, which owns leasehold land interests in Hawaii. The Company generates the majority of its revenue from the Oil and Natural Gas segment. The company operates in two geographic regions, the United States and Canada, with Canada contributing the majority of revenue.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.